Changing Trends in the Epidemiology of Pediatric Lead Exposure
Neonatal Hair Analysis Contribution to Establishing a Gestational Drug Exposure Profile and Predicting a Withdrawal Syndrome
Determination of Epirubicin and Its Metabolite Epirubicinol in Saliva and Plasma by HPLC
An Automated HPLC Method to Determine Intracellular Vincristine Concentrations in Mononuclear Cells of Children with Acute Lymphoblastic Leukemia
Long-Term Pharmacokinetic Study of the Novel Combination of Tacrolimus and Sirolimus in De Novo Renal Allograft Recipients
Measurement of β-Methyldigoxin Level in Serum from Patients by Enzyme Immunoassay Using Novel Specific Antiserum with a Phenyl Boric Acid Column
Serum Concentrations and Effects of Gabapentin and Vigabatrin
Effects of the CYP 2D6 Genotype and Cigarette Smoking on the Steady-State Plasma Concentrations of Fluvoxamine and Its Major Metabolite Fluvoxamino Acid in Japanese Depressed Patients
Monitoring Clozapine
Effects of Itraconazole on the Plasma Kinetics of Quazepam and Its Two Active Metabolites after a Single Oral Dose of the Drug
A New Turbidometric Digoxin Immunoassay on the ADVIA 1650 Analyzer Is Free from Interference by Spironolactone, Potassium Canrenoate, and Their Common Metabolite Canrenone
Itraconazole-Tacrolimus Drug Interaction
“Lack of Clinically Significant Interference by Spironolactone with the Axsym Digoxin II Assay” Only Applies to Low-Dose Therapy with Spironolactone